092730 — NeoPharm Co Cashflow Statement

0.000.00%

Last trade - 00:00

Consumer DefensivesAdventurousSmall CapSuper Stock

Annual cashflow statement for NeoPharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	18,131	17,713	17,027	23,213	23,065
Depreciation
Amortisation
Non-Cash Items	5,217	5,456	5,207	3,519	2,891
Unusual Items
Other Non-Cash Items
Changes in Working Capital	-7,726	-2,939	-5,637	-5,088	-10,421
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	17,074	21,681	18,161	23,263	18,631
Capital Expenditures	-730	-478	-806	-20,828	-3,077
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-4,009	-16,211	-7,993	4,475	-3,148
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-4,739	-16,689	-8,800	-16,353	-6,225
Financing Cash Flow Items	16.2	-62.1	219	91.8	4.94
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-6,569	-9,519	-5,750	-5,917	-6,495
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	5,673	-4,140	3,834	998	6,353